<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
    <channel>
        <title>Pharmaceutical Technology via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Pharmaceutical Technology' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Pharmaceutical+Technology&t=Pharmaceutical+Technology&s=Search&f=source]]></link>
        <lastBuildDate>Thu, 09 Feb 2012 01:31:35 +0100</lastBuildDate>
        <item>
            <title>Combino Pharm - A Trusted Provider of Contract Development Services</title>
            <link>http://www.medworm.com/index.php?rid=5669360&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fcontract%2Fcombinopharm%2Fpresscombino-pharm-contract-development.html</link>
            <description>Combino Pharm's R&amp;D facilities are based in Sant Joan Despí, Barcelona, with an R&amp;D Center of 1,600m², including a complete lab exclusively dedicated to formulation and process design and another exclusively dedicated to analytical development. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5669360</comments>
            <pubDate>Wed, 08 Feb 2012 14:13:00 +0100</pubDate>
            <guid isPermaLink="false">5669360</guid>        </item>
        <item>
            <title>Matcon Pacific to Hold Lean Powder Processing Conferences in June</title>
            <link>http://www.medworm.com/index.php?rid=5669361&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fpackaging%2Fmatconpacific%2Fpressmatcon-lean-powder-processing-conferences.html</link>
            <description>Matcon Pacific will hold a Lean Powder Processing Conference in both Melbourne and Sydney during June 2012. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5669361</comments>
            <pubDate>Wed, 08 Feb 2012 13:22:00 +0100</pubDate>
            <guid isPermaLink="false">5669361</guid>        </item>
        <item>
            <title>DEC MicroJet 10: Ideal for Pre-Clinical Trials and NCE Product Development</title>
            <link>http://www.medworm.com/index.php?rid=5669362&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fprocess_automation%2Fdec-group%2Fpressdec-microjet.html</link>
            <description>The launch of the DEC MicroJet 10, the world's smallest fully functioning jet mill, now completes our research and development range of jet mills. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5669362</comments>
            <pubDate>Wed, 08 Feb 2012 12:41:00 +0100</pubDate>
            <guid isPermaLink="false">5669362</guid>        </item>
        <item>
            <title>GlaxoSmithKline to expand Melbourne site</title>
            <link>http://www.medworm.com/index.php?rid=5669364&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsglaxosmithkline-to-expand-melbourne-site</link>
            <description>UK-based pharmaceutical major GlaxoSmithKline (GSK) has announced plans to invest A$60m to expand its manufacturing and drug development activities at its Boronia facility near Melbourne, Australia. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5669364</comments>
            <pubDate>Wed, 08 Feb 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5669364</guid>        </item>
        <item>
            <title>Brain cells made in US lab open doors for Parkinson’s research</title>
            <link>http://www.medworm.com/index.php?rid=5669363&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsbrain-cells-made-in-us-lab-open-doors-for-parkinsons-research</link>
            <description>US scientists have paved the way for major research into Parkinson’s disease after successfully making human brain cells in the lab that are an exact replica of a genetically-caused form of the illness. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5669363</comments>
            <pubDate>Wed, 08 Feb 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5669363</guid>        </item>
        <item>
            <title>UCB announces robotic drug discovery scientist success</title>
            <link>http://www.medworm.com/index.php?rid=5669366&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsucb-announces-robotic-drug-discovery-scientist-success</link>
            <description>UCB has announced the successful completion of its first fully automated lead discovery experiment, achieved in collaboration with Cyclofluidic and its technology platform. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5669366</comments>
            <pubDate>Tue, 07 Feb 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5669366</guid>        </item>
        <item>
            <title>UK Health Ministers “in denial” over drug shortages, says AAH</title>
            <link>http://www.medworm.com/index.php?rid=5669365&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsuk-health-ministers-in-denial-over-drug-shortages-says-aah</link>
            <description>A UK health minister has been criticised for his remarks regarding the &quot;inevitable&quot; drug shortages in the country. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5669365</comments>
            <pubDate>Tue, 07 Feb 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5669365</guid>        </item>
        <item>
            <title>Eisai Knowledge Centre, Visakhapatnam</title>
            <link>http://www.medworm.com/index.php?rid=5669370&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fprojects%2Feisai-knowledge-centre%2F</link>
            <description>Eisai Knowledge Centre is located in the Special Economic Zone at the Jawaharlal Nehru Pharma City in Visakhapatnam, Andhra Pradesh, India. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5669370</comments>
            <pubDate>Mon, 06 Feb 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5669370</guid>        </item>
        <item>
            <title>Merck Serono licenses Threshold cancer drug</title>
            <link>http://www.medworm.com/index.php?rid=5669369&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsmerck-serono-licenses-threshold-cancer-drug</link>
            <description>Merck Serono, a unit of German pharmaceutical manufacturer Merck, has signed a licensing agreement with US-based biotechnology firm Threshold Pharmaceuticals for the development and commercialisation of TH-302. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5669369</comments>
            <pubDate>Mon, 06 Feb 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5669369</guid>        </item>
        <item>
            <title>Medical cargo theft: securing the supply chain</title>
            <link>http://www.medworm.com/index.php?rid=5669368&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Ffeatures%2Ffeaturemedical-cargo-theft-securing-the-supply-chain%2F</link>
            <description>With companies outsourcing clinical trials to emerging nations, medical cargo theft has become a major concern. Prior to Arena International's Clinical Trial Supply Europe, Elisabeth Fischer talks to Cathy Brown, process improvement manager within se… (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5669368</comments>
            <pubDate>Mon, 06 Feb 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5669368</guid>        </item>
        <item>
            <title>Taiwan vaccine manufacturer to be listed on stock exchange</title>
            <link>http://www.medworm.com/index.php?rid=5669367&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewstaiwan-vaccine-manufacturer-to-be-listed-on-stock-exchange</link>
            <description>Adimmune Corp, a vaccine manufacturer based in Taiwan, could be list on the stock market in March at the earliest, the company announced today. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5669367</comments>
            <pubDate>Mon, 06 Feb 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5669367</guid>        </item>
        <item>
            <title>Merck receives FDA approval for Janumet</title>
            <link>http://www.medworm.com/index.php?rid=5661324&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsmerck-receives-fda-approval-for-janumet</link>
            <description>US-based pharmaceutical company Merck has received US Food and Drug Administration (FDA) approval for Janumet XR, its new type 2 diabetes treatment. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5661324</comments>
            <pubDate>Fri, 03 Feb 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5661324</guid>        </item>
        <item>
            <title>New cost-cutting Medicaid rule could save US billions</title>
            <link>http://www.medworm.com/index.php?rid=5661323&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsnew-cost-cutting-medicaid-rule-could-save-us-billions</link>
            <description>A newly proposed cost-cutting rule implemented into the US Medicaid programme could save the country up to $17.7bn over five years, say US health officials. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5661323</comments>
            <pubDate>Fri, 03 Feb 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5661323</guid>        </item>
        <item>
            <title>Evonik Pharma Polymers-Functional Pharmaceutical Excipients and Advanced Formulation Solutions</title>
            <link>http://www.medworm.com/index.php?rid=5651455&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fexcipients%2Fevonik-pharma-polymers%2F</link>
            <description>With its Pharma Polymers product line, Evonik is a major provider of functional pharmaceutical excipients and advanced formulation solutions. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5651455</comments>
            <pubDate>Thu, 02 Feb 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5651455</guid>        </item>
        <item>
            <title>AstraZeneca job cuts more severe than feared</title>
            <link>http://www.medworm.com/index.php?rid=5651454&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsastrazeneca-job-cuts-more-severe-than-feared</link>
            <description>Job cuts at Anglo-Swedish pharmaceutical firm AstraZeneca (AZ) are to be worse than feared, following an announcement made by the company amid rumours previously reported in the Sunday Times. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5651454</comments>
            <pubDate>Thu, 02 Feb 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5651454</guid>        </item>
        <item>
            <title>Less is more: why rare disease funding is on the up</title>
            <link>http://www.medworm.com/index.php?rid=5651453&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Ffeatures%2Ffeatureless-is-more-why-rare-disease-funding-is-on-the-up%2F</link>
            <description>Despite reductions in R&amp;D spending, clinical trials for rare diseases are going full steam ahead. Elly Earls speaks to Alastair Kent of Genetic Alliance UK, Tim Cote of the National Organization for Rare Disorders (NORD) and Dr Steve Groft of the Off… (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5651453</comments>
            <pubDate>Thu, 02 Feb 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5651453</guid>        </item>
        <item>
            <title>Generic Liptor causes Pfizer profit slump</title>
            <link>http://www.medworm.com/index.php?rid=5651452&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsgeneric-liptor-causes-pfizer-profit-slump</link>
            <description>Pharmaceutical major Pfizer has announced a 50% slump in net income for Q4 2011 as the company suffers at the hands of generic versions of its cholesterol blockbuster Lipitor. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5651452</comments>
            <pubDate>Thu, 02 Feb 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5651452</guid>        </item>
        <item>
            <title>Scavenging Technologies from Johnson Matthey-Product Purification and Recovery of Precious and Base Metals</title>
            <link>http://www.medworm.com/index.php?rid=5651451&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fpurification%2Fscavenging-technologies2%2F</link>
            <description>Scavenging Technologies, a business unit of Johnson Matthey dedicated to product purification and recovery of precious and base metals, offers an extensive range of pure, fast and effective metal scavengers for use in the pharmaceutical industry. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5651451</comments>
            <pubDate>Thu, 02 Feb 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5651451</guid>        </item>
        <item>
            <title>SCHOTT Appoints Vice President of Global Syringe Business</title>
            <link>http://www.medworm.com/index.php?rid=5651456&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fpackaging%2Fschott-packaging%2Fpressschott-appoints-vice-president-of-global-syringe-business.html</link>
            <description>SCHOTT has appointed Christophe Muguet as vice president of its global syringe business. He leads this area's business activities as part of SCHOTT Pharmaceutical Packaging from the offices in St Gallen, Switzerland. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5651456</comments>
            <pubDate>Wed, 01 Feb 2012 16:36:47 +0100</pubDate>
            <guid isPermaLink="false">5651456</guid>        </item>
        <item>
            <title>Reports fuel rumours of further job cuts at AstraZeneca</title>
            <link>http://www.medworm.com/index.php?rid=5651458&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsrumoured-job-cuts-at-astrazeneca</link>
            <description>AstraZeneca is rumoured to be cutting up to 3,000 further jobs ahead of posting its full-year financial results, reports published in the Sunday Times suggest. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5651458</comments>
            <pubDate>Wed, 01 Feb 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5651458</guid>        </item>
        <item>
            <title>Roche’s skin cancer drug Erivedge given FDA nod</title>
            <link>http://www.medworm.com/index.php?rid=5651457&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsroches-skin-cancer-drug-erivedge-given-fda-nod</link>
            <description>Roche’s skin cancer drug Eviredge, developed in collaboration with Curis, has been approved by the US Food and Drug Administration. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5651457</comments>
            <pubDate>Wed, 01 Feb 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5651457</guid>        </item>
        <item>
            <title>FDA approves Amylin’s diabetes drug Bydureon</title>
            <link>http://www.medworm.com/index.php?rid=5651462&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsfda-approves-amylins-diabetes-drug-bydureon</link>
            <description>The US Food and Drug Administration (FDA) has approved Amylin’s once-weekly diabetes drug Bydureon at the third time of asking. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5651462</comments>
            <pubDate>Tue, 31 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5651462</guid>        </item>
        <item>
            <title>Pakistan Supreme Court orders release of pharma owners</title>
            <link>http://www.medworm.com/index.php?rid=5651461&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewspakistan-supreme-court-orders-release-of-pharma-owners</link>
            <description>Pakistan’s Supreme Court has ordered the release of two owners of pharmaceutical companies as part of an investigation into deaths caused by the reaction from drugs distributed by the Punjab Institute of Cardiology. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5651461</comments>
            <pubDate>Tue, 31 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5651461</guid>        </item>
        <item>
            <title>2012 Olympics Anti-Doping Laboratory</title>
            <link>http://www.medworm.com/index.php?rid=5651460&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fprojects%2F2012-olympics-anti-doping-laboratory%2F</link>
            <description>The 2012 London Olympics will be the first Olympic event to have an anti-doping laboratory sponsored by a pharmaceutical company. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5651460</comments>
            <pubDate>Tue, 31 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5651460</guid>        </item>
        <item>
            <title>Ahead in the cloud – a new home for clinical trial data</title>
            <link>http://www.medworm.com/index.php?rid=5651459&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Ffeatures%2Ffeatureahead-in-the-cloud-a-new-home-for-clinical-trial-data%2F</link>
            <description>As the volume and complexity of clinical trial data grows, scientists need new ways to filter information. Elly Earls speaks to SAFE Bio-Pharma's Mollie Shields-Uehling and IBM's Chris Hines about why moving to the cloud could reduce clinical trial c… (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5651459</comments>
            <pubDate>Tue, 31 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5651459</guid>        </item>
        <item>
            <title>Amgen to acquire Micromet</title>
            <link>http://www.medworm.com/index.php?rid=5651465&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsamgen-to-acquire-micromet</link>
            <description>US-based pharmaceutical firm Amgen is to acquire the Germany-based biotechnology company Micromet in a deal that values the company at approximately $1.16bn. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5651465</comments>
            <pubDate>Mon, 30 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5651465</guid>        </item>
        <item>
            <title>Gulf Pharmaceutical Industries (Julphar) Insulin Production Facility</title>
            <link>http://www.medworm.com/index.php?rid=5651464&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fprojects%2Fgulf-pharmaceutical-industries-julphar-insulin-production-facility-uae%2F</link>
            <description>Gulf Pharmaceutical Industries, known popularly as Julphar, is set to inaugurate the first ever insulin production facility in the Middle East. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5651464</comments>
            <pubDate>Mon, 30 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5651464</guid>        </item>
        <item>
            <title>Big Pharma to collaborate to combat neglected diseases</title>
            <link>http://www.medworm.com/index.php?rid=5651463&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsbig-pharma-to-collaborate-to-combat-neglected-diseases</link>
            <description>Some of the world’s largest pharmaceutical companies are joining forces with health organisations to donate drugs aimed at controlling or eradicating ten neglected tropical diseases by 2020. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5651463</comments>
            <pubDate>Mon, 30 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5651463</guid>        </item>
        <item>
            <title>Pakistan agencies arrest officials after fake drugs cause cardiac patients deaths</title>
            <link>http://www.medworm.com/index.php?rid=5651466&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsindian-agencies-seize-hospital-records-after-fake-drugs-cause-cardiac-patient-deaths</link>
            <description>Federal agencies in Pakistan are investigating the cause of over cardiac patient deaths linked to fake drugs administered to some 40,000 patients at a Government run hospital. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5651466</comments>
            <pubDate>Fri, 27 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5651466</guid>        </item>
        <item>
            <title>Indian agencies seize hospital records after fake drugs cause cardiac patients deaths</title>
            <link>http://www.medworm.com/index.php?rid=5639957&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsindian-agencies-seize-hospital-records-after-fake-drugs-cause-cardiac-patient-deaths</link>
            <description>Indian federal agencies investigating the deaths of cardiac patients caused by phony drugs have seized medicine stocks and hospital records, and have announced that the officials of three drug companies are wanted for questioning. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5639957</comments>
            <pubDate>Fri, 27 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5639957</guid>        </item>
        <item>
            <title>Xenoport accuses GSK of contract breach</title>
            <link>http://www.medworm.com/index.php?rid=5639956&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsxenoport-accuses-gsk-of-contract-breach</link>
            <description>US-based Xenoport has accused UK-based pharmaceutical major GlaxoSmithKline (GSK) of a breach of contract and is threatening to end the pact relating to restless legs syndrome medication Horizant. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5639956</comments>
            <pubDate>Fri, 27 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5639956</guid>        </item>
        <item>
            <title>H3 Biomedicine New Research Facility</title>
            <link>http://www.medworm.com/index.php?rid=5631139&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fprojects%2Fh3-biomedicine-new-research-facility%2F</link>
            <description>H3 Biomedicine, the American subsidiary of Tokyo-based company Eisai, opened its new research facility in Cambridge, in the state of Massachusetts, US, in December 2011. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5631139</comments>
            <pubDate>Thu, 26 Jan 2012 00:15:00 +0100</pubDate>
            <guid isPermaLink="false">5631139</guid>        </item>
        <item>
            <title>Minimizing Time to Market: Developing Consumer Health Products Under the US OTC Drug Monograph</title>
            <link>http://www.medworm.com/index.php?rid=5631145&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fdownloads%2Fwhitepapers%2Fdrug_delivery%2Ffiledeveloping-health-products-under-otc%2F</link>
            <description>With the tightening of R&amp;D budgets and increased pressure from financial stakeholders, the pharmaceutical industry faces a great challenge in bringing profitable drug products to market both quickly and efficiently. By choosing to develop new and pat… (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5631145</comments>
            <pubDate>Thu, 26 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5631145</guid>        </item>
        <item>
            <title>Membrana Launches Online Membrane Contactor Store</title>
            <link>http://www.medworm.com/index.php?rid=5631144&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fpurification%2Fmembrana-deaeration%2Fpressmembrana-online-store.html</link>
            <description>Membrana-Charlotte, a division of Celgard, has announced the launch of its new online store for membrane contactors. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5631144</comments>
            <pubDate>Thu, 26 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5631144</guid>        </item>
        <item>
            <title>Novartis net profit falls 47%</title>
            <link>http://www.medworm.com/index.php?rid=5631143&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsnovartis-net-profit-falls-47</link>
            <description>Novartis has reported that its fourth quarter net profit fell 47% to $1.21bn as the company felt the impact of a previously disclosed charge of $900m, relating to a forecasted decline for sales of its Tekturna drug. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5631143</comments>
            <pubDate>Thu, 26 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5631143</guid>        </item>
        <item>
            <title>Hodess Construction Releases New Cleanroom Project White Paper</title>
            <link>http://www.medworm.com/index.php?rid=5631142&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fcleanroom%2Fhodess-construction%2Fpresshodess-cleanroom-whitepaper.html</link>
            <description>Hodess Construction is a leader in cleanroom design and construction. As a cleanroom specialist, Hodess can provide everything you need for your cleanroom project. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5631142</comments>
            <pubDate>Thu, 26 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5631142</guid>        </item>
        <item>
            <title>Hikma and Ergomed announce clinical trial partnership</title>
            <link>http://www.medworm.com/index.php?rid=5631141&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewshikma-and-ergomed-announce-clinical-trial-partnership</link>
            <description>Hikma Pharmaceuticals has partnered with Ergomed in order for the latter to manage clinical trials involving Hikma treatments. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5631141</comments>
            <pubDate>Thu, 26 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5631141</guid>        </item>
        <item>
            <title>Sofrigam-Thermal Insulated and Cooling Packaging for Cold-Chain Storage and Distribution</title>
            <link>http://www.medworm.com/index.php?rid=5631140&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fmaterials-handling%2Fsofrigam%2F</link>
            <description>Created 25 years ago, SOFRIGAM has grown rapidly in the past years to become a leading company in the design, testing, manufacture and qualification of thermal insulated (isothermal) and refrigeratin... (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5631140</comments>
            <pubDate>Thu, 26 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5631140</guid>        </item>
        <item>
            <title>Priorclave Offers Autoclaves for Designated CAT3 Laboratories</title>
            <link>http://www.medworm.com/index.php?rid=5631146&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Flab_equip%2Fpriorclave-autoclaves%2Fpressautoclaves-for-cat3-laboratories.html</link>
            <description>The Compact C40 vacuum autoclave is the first priorclave to become available with stand-off legs, providing easy access beneath the steam steriliser for cleaning and disinfection of laboratory work surfaces to prevent the spread of virus and eliminat… (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5631146</comments>
            <pubDate>Wed, 25 Jan 2012 15:34:00 +0100</pubDate>
            <guid isPermaLink="false">5631146</guid>        </item>
        <item>
            <title>Novo Nordisk to establish US diabetes research centre</title>
            <link>http://www.medworm.com/index.php?rid=5631149&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsnovo-nordisk-to-establish-us-diabetes-research-centre</link>
            <description>Denmark-based pharmaceutical company Novo Nordisk is to create a research and development centre in Seattle, US, for type 1 diabetes, in order to further research into a disease that the company claims has been neglected. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5631149</comments>
            <pubDate>Wed, 25 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5631149</guid>        </item>
        <item>
            <title>Roche hostile bid for Illumina deemed “full and fair”</title>
            <link>http://www.medworm.com/index.php?rid=5631148&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsroche-hostile-bid-for-illumina-full-and-fair</link>
            <description>Switzerland-based drugmaker Roche has described its $5.7bn hostile offer for US gene sequencing company Illumina as “full and fair”, confirming that it does not plan to increase its bid. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5631148</comments>
            <pubDate>Wed, 25 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5631148</guid>        </item>
        <item>
            <title>Pharma Technology Focus - Issue 9</title>
            <link>http://www.medworm.com/index.php?rid=5631147&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Ffeatures%2Ffeaturepharma-technology-focus-issue-9%2F</link>
            <description>In this issue we investigate how rapidly evolving drug delivery methods are helping to make medicines more effective. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5631147</comments>
            <pubDate>Wed, 25 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5631147</guid>        </item>
        <item>
            <title>Matcon Pacific-IBC Systems for the Pharmaceutical Industry</title>
            <link>http://www.medworm.com/index.php?rid=5631154&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fpackaging%2Fmatconpacific%2F</link>
            <description>Matcon specialises in providing intermediate bulk containers (IBCs) and associated equipment for the handling of powders, granules, tablets and other materials. Matcon has offices around the world an... (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5631154</comments>
            <pubDate>Tue, 24 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5631154</guid>        </item>
        <item>
            <title>Hodess Construction Cleanroom Project for Collagen Matrix</title>
            <link>http://www.medworm.com/index.php?rid=5631153&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fdownloads%2Fwhitepapers%2Fcleanroom%2Ffilehodess-construction-cleanroom-project%2F</link>
            <description>Hodess Construction was contracted to provided a complete turnkey demolition and renovation of an existing building to expand Collagen Matrix's production capacities and to relocate them to a new space. The project included demolition of 10,000 squar… (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5631153</comments>
            <pubDate>Tue, 24 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5631153</guid>        </item>
        <item>
            <title>Watson to acquire Ascent Pharmahealth</title>
            <link>http://www.medworm.com/index.php?rid=5631152&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewswatson-to-acquire-ascent-pharmahealth</link>
            <description>US-based Watson Pharmaceuticals has acquired Strides Arcolab subsidiary Ascent Pharmahealth in a deal worth A$375m (US$393m). (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5631152</comments>
            <pubDate>Tue, 24 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5631152</guid>        </item>
        <item>
            <title>Baxter begins final trial on Alzheimer’s drug</title>
            <link>http://www.medworm.com/index.php?rid=5631151&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsbaxter-begins-final-trial-on-alzheimers-drug</link>
            <description>Baxter International is to begin a second Phase III clinical trial on its Gammagard liquid intravenous drug for the treatment of mild to moderate Alzheimer’s disease. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5631151</comments>
            <pubDate>Tue, 24 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5631151</guid>        </item>
        <item>
            <title>Novel Formulations to Improve the Control of Emesis</title>
            <link>http://www.medworm.com/index.php?rid=5631150&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fdownloads%2Fwhitepapers%2Fdrug_delivery%2Ffilenovel-formulations-to-control-emesis%2F</link>
            <description>Reformulation is a key strategy for product development and helps address the challenges of the current market, such as longer new chemical entity (NCE) development timelines, fewer new drug approvals, increasing costs, looming patent expirations and… (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5631150</comments>
            <pubDate>Tue, 24 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5631150</guid>        </item>
        <item>
            <title>Merck settles Vioxx litigation in Canada</title>
            <link>http://www.medworm.com/index.php?rid=5621691&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsmerck-settles-vioxx-litigation-in-canada</link>
            <description>Merck has agreed to pay at least $21.5m to resolve claims against its painkiller drug Vioxx in Canada. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5621691</comments>
            <pubDate>Mon, 23 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5621691</guid>        </item>
        <item>
            <title>Going with the flow: Continuous manufacturing</title>
            <link>http://www.medworm.com/index.php?rid=5621690&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Ffeatures%2Ffeaturegoing-with-the-flow-continuous-manufacturing%2F</link>
            <description>As manufacturing models embrace process analytical technology, big pharma has to reassess the way it produces drugs. Elisabeth Fischer profiles the opportunities and stumbling blocks of continuous manufacturing and finds out how it will revolutionise… (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5621690</comments>
            <pubDate>Mon, 23 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5621690</guid>        </item>
        <item>
            <title>Unither-Blow, Fill and Seal Technology, Effervescent Tablets and Liquid Stick-Packs</title>
            <link>http://www.medworm.com/index.php?rid=5621689&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fcontract%2Funither%2F</link>
            <description>Unither is an independent pharmaceutical company specialising in the development and contract manufacture of the pharmaceutical formulations that patients and prescribers prefer :Sterile unit-dose vi... (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5621689</comments>
            <pubDate>Mon, 23 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5621689</guid>        </item>
        <item>
            <title>Fuchs Lubricants-High-Quality Pharmaceutical Excipients</title>
            <link>http://www.medworm.com/index.php?rid=5621688&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fexcipients%2Ffuchs-lubricants%2F</link>
            <description>Fuchs Lubricants has over 40 years' successful experience in the production of excipients in the form of white and yellow soft paraffins and white oils. These products are used by pharmaceutical comp... (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5621688</comments>
            <pubDate>Mon, 23 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5621688</guid>        </item>
        <item>
            <title>A-consult-Professional Regulatory Affairs and Drug Safety Services for Pharmaceutical Companies</title>
            <link>http://www.medworm.com/index.php?rid=5621687&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fconsult%2Fa-consult%2F</link>
            <description>A-consult offers professional assistance to the pharmaceutical industry within all areas of regulatory affairs and drug safety.A-consult supplies you with the necessary expertise as our team of highl... (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5621687</comments>
            <pubDate>Mon, 23 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5621687</guid>        </item>
        <item>
            <title>Cannabis-based cancer pain drug could hit US shelves</title>
            <link>http://www.medworm.com/index.php?rid=5621686&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewscannabis-based-cancer-pain-drug-could-hit-us-shelves</link>
            <description>A cannabis-based drug designed to treat cancer pain, developed by UK-based GW Pharma, could be available in the US by the end of 2013. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5621686</comments>
            <pubDate>Mon, 23 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5621686</guid>        </item>
        <item>
            <title>Peter Greven-High-Quality Magnesium Stearates for Efficient Tabletting</title>
            <link>http://www.medworm.com/index.php?rid=5621685&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fexcipients%2Fpeter-greven%2F</link>
            <description>Peter Greven Group is a producer of oleochemical additives and auxiliaries. The company was founded in 1923 as a family-owned company. Due to a consistent growth and further developments Peter Greven... (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5621685</comments>
            <pubDate>Mon, 23 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5621685</guid>        </item>
        <item>
            <title>BTG receives US Voraxaze approval</title>
            <link>http://www.medworm.com/index.php?rid=5612188&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsbtg-receives-us-voraxaze-approval</link>
            <description>UK-based pharmaceutical company BTG has received US Food and Drug Adminsitration (FDA) approval for its Voraxaze medication, which is used to treat patients suffering from toxic levels of methotrexate due to kidney failure. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5612188</comments>
            <pubDate>Fri, 20 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5612188</guid>        </item>
        <item>
            <title>AstraZeneca and Bristol-Myers Squibb diabetes drug rejected by FDA</title>
            <link>http://www.medworm.com/index.php?rid=5612187&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsastrazeneca-bristol-myers-squibb-diabetes-drug-rejected-by-fda</link>
            <description>Approval for AstraZeneca and Bristol-Myers Squibb’s diabetes drug dapagliflozin has been rejected by the US Food and Drug Administration. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5612187</comments>
            <pubDate>Fri, 20 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5612187</guid>        </item>
        <item>
            <title>Exeltainer-Insulated Packaging Concepts</title>
            <link>http://www.medworm.com/index.php?rid=5612194&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fmaterials-handling%2Fexeltainer%2F</link>
            <description>Exeltainer is a European company that specialises in the design, manufacture and validation of insulated packaging systems to maintain the cold chain of pharmaceutical and biotechnological products during storage and distribution. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5612194</comments>
            <pubDate>Thu, 19 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5612194</guid>        </item>
        <item>
            <title>Jobs lost as Takeda restructures</title>
            <link>http://www.medworm.com/index.php?rid=5612193&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsjobs-lost-as-takeda-restructures</link>
            <description>Restructuring at Japan-headquartered Takeda Pharmaceuticals is to result in the loss of 2,800 jobs, with European-based positions likely to be the hardest hit. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5612193</comments>
            <pubDate>Thu, 19 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5612193</guid>        </item>
        <item>
            <title>piCHEM-Peptides for Therapeutic and Diagnostic Research, and Peptide-Based APIs</title>
            <link>http://www.medworm.com/index.php?rid=5612192&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Foligos%2Fpichem%2F</link>
            <description>piCHEM manufactures peptides for therapeutic and diagnostic research applications. piCHEM has been approved for GMP production since 2002 and is therefore able to extend its services to pharmaceutical-grade peptide-based APIs. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5612192</comments>
            <pubDate>Thu, 19 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5612192</guid>        </item>
        <item>
            <title>Antidepressants cause three times more falls in people with dementia</title>
            <link>http://www.medworm.com/index.php?rid=5612191&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsantidepressants-cause-three-times-more-falls-in-people-with-dementia-study</link>
            <description>Elderly people with dementia are three times more likely to have an injurious fall if they take antidepressants, according to research published in the British Journal of Clinical Pharmacology. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5612191</comments>
            <pubDate>Thu, 19 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5612191</guid>        </item>
        <item>
            <title>Aptalis Pharma Announces FDA Approval of NDA for Oral Powder Formulation of Viread®, Co-Developed with Gilead Sciences</title>
            <link>http://www.medworm.com/index.php?rid=5612190&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fdrug_delivery%2Feurand%2Fpressfda-approval-viread.html</link>
            <description>Aptalis Pharma has announced that the US Food and Drug Administration (FDA) has approved a new drug application (NDA) for Gilead Sciences' Viread® (tenofovir disoproxil fumarate) oral powder in combination with other antiretroviral agents for the tre… (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5612190</comments>
            <pubDate>Thu, 19 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5612190</guid>        </item>
        <item>
            <title>Insulated Packaging Solutions from Exeltainer</title>
            <link>http://www.medworm.com/index.php?rid=5612189&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fdownloads%2Fwhitepapers%2Fmaterials-handling%2Ffileinsulated-packaging-solutions%2F</link>
            <description>Exeltainer designs, manufactures and validates insulated systems for maintaining the cold chain through the whole shipping and distribution process. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5612189</comments>
            <pubDate>Thu, 19 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5612189</guid>        </item>
        <item>
            <title>Singapore sees rise in pharmaceutical shipments</title>
            <link>http://www.medworm.com/index.php?rid=5612199&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewssingapore-sees-rise-in-pharmaceutical-shipments</link>
            <description>A rise in pharmaceutical shipments to Europe led to an unexpected lift in Singapore’s non-oil exports last month, trade promotion agency International Enterprise Singapore has said. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5612199</comments>
            <pubDate>Wed, 18 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5612199</guid>        </item>
        <item>
            <title>Micromeritics Releases MicroActive - Innovative Interactive Data Analysis Software</title>
            <link>http://www.medworm.com/index.php?rid=5612198&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Flab_equip%2Fmicromeritics%2Fpressmicromeritics-microactive.html</link>
            <description>Micromeritics' new and innovative MicroActive data analysis software allows users to interactively evaluate isotherm data from Micromeritics' ASAP, TriStar, and Gemini gas adsorption instruments. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5612198</comments>
            <pubDate>Wed, 18 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5612198</guid>        </item>
        <item>
            <title>Totally drug-resistant TB found in Mumbai</title>
            <link>http://www.medworm.com/index.php?rid=5612197&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewstotally-drug-resistant-tb-found-in-mumbai</link>
            <description>A strain of tuberculosis said to be resistant to all antibiotics has been reported in India. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5612197</comments>
            <pubDate>Wed, 18 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5612197</guid>        </item>
        <item>
            <title>Magnesia-Magnesium Compounds and Calcium Compounds</title>
            <link>http://www.medworm.com/index.php?rid=5612196&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fchemicals%2Fmagnesia%2F</link>
            <description>Magnesia GmbH, Lüneburg, has been successfully supplying customers around the world with high-quality raw materials for more than 20 years. Excellent service, customer satisfaction and high quality p... (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5612196</comments>
            <pubDate>Wed, 18 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5612196</guid>        </item>
        <item>
            <title>SAFC Verona HPAPI Manufacturing Facility</title>
            <link>http://www.medworm.com/index.php?rid=5612195&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fprojects%2Fsafc-verona-hpapi-manufacturing-facility%2F</link>
            <description>SAFC, a business division of Sigma-Aldrich, is a custom manufacturer and services provider for pharmaceutical and biopharmaceutical companies. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5612195</comments>
            <pubDate>Wed, 18 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5612195</guid>        </item>
        <item>
            <title>Novartis to cut nearly 2,000 US pharma jobs</title>
            <link>http://www.medworm.com/index.php?rid=5612200&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsnovartis-to-cut-nearly-2000-us-pharma-jobs</link>
            <description>Novartis will cut nearly 2,000 jobs in the US ahead of the patent expiration of its Diovan (valsartan) drug and an expected reduction in demand for Rasilez / Tekturna (aliskiren) following the termination of the ALTITUDE clinical study. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5612200</comments>
            <pubDate>Tue, 17 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5612200</guid>        </item>
        <item>
            <title>Roquette Pharma-Global Supplier of Pharmaceutical Excipients and Actives</title>
            <link>http://www.medworm.com/index.php?rid=5600094&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fexcipients%2Froquette-pharma%2F</link>
            <description>Roquette is a global manufacturer of pharmaceutical excipients and actives, having been a major supplier to the pharmaceutical industry for more than 30 years and contributing through the reliability... (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5600094</comments>
            <pubDate>Tue, 17 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5600094</guid>        </item>
        <item>
            <title>FDA calls for strictest warning on drug linked to brain infection</title>
            <link>http://www.medworm.com/index.php?rid=5600093&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsfda-calls-for-strictest-warning-on-drug-linked-to-brain-infection</link>
            <description>The US Food and Drug Administration plans to strengthen the warning label on lymphoma drug Adcetris over concerns that it may be linked to a rare, but deadly brain infection. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5600093</comments>
            <pubDate>Tue, 17 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5600093</guid>        </item>
        <item>
            <title>Lloydspharmacy to offer 'smart' drugs packages</title>
            <link>http://www.medworm.com/index.php?rid=5600092&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewslloydspharmacy-to-offer-smart-drugs-packages</link>
            <description>UK-based pharmacy chain Lloydspharmacy is to launch a service offering customers 'intelligent' medicines, allowing a patient to follow doctors’ orders as required. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5600092</comments>
            <pubDate>Tue, 17 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5600092</guid>        </item>
        <item>
            <title>World Courier-Fully Integrated GxP-Compliant Global Transport and Storage</title>
            <link>http://www.medworm.com/index.php?rid=5600091&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fmaterials-handling%2Fworld-courier%2F</link>
            <description>For the past 40 years, World Courier has been recognised as the 'gold standard' for worldwide time- and temperature-sensitive transportation services to the pharmaceutical industry. Relying on its ow... (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5600091</comments>
            <pubDate>Tue, 17 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5600091</guid>        </item>
        <item>
            <title>US user fee programmes to speed up drug approvals</title>
            <link>http://www.medworm.com/index.php?rid=5600099&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsus-user-fee-programmes-to-speed-up-drug-approvals</link>
            <description>The US Food and Drug Administration has recommended three user fee programmes that are designed to help speed up the delivery of safe and effective drugs to patients. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5600099</comments>
            <pubDate>Mon, 16 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5600099</guid>        </item>
        <item>
            <title>Investigator relations: Road to success for clinical trials</title>
            <link>http://www.medworm.com/index.php?rid=5600098&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Ffeatures%2Ffeatureinvestigator-relations-road-to-success-for-clinical-trials%2F</link>
            <description>Identifying and selecting the right investigator has a significant impact on the success or failure of a clinical trial. In the run-up to Arena International's Outsourcing in Clinical Trials West Coast event, Elisabeth Fischer ask Wendy Verret, vice-… (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5600098</comments>
            <pubDate>Mon, 16 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5600098</guid>        </item>
        <item>
            <title>AstraZeneca to enter into European evidence collaboration</title>
            <link>http://www.medworm.com/index.php?rid=5600097&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsastrazeneca-to-enter-into-european-evidence-collaboration</link>
            <description>AstraZeneca has entered into a three-year collaboration agreement with healthcare information and technology provider IMS Health. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5600097</comments>
            <pubDate>Mon, 16 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5600097</guid>        </item>
        <item>
            <title>Recent Milestones Mark Ropack's 35th Anniversary and Position the Contract Packager for Growth</title>
            <link>http://www.medworm.com/index.php?rid=5600096&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fcontract%2Fropack%2Fpressropack-35th-anniversary.html</link>
            <description>During its 35th anniversary, Ropack celebrates its notable past which continues to shape the company. At the same time, it demonstrates that it is a company clearly focused on the future. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5600096</comments>
            <pubDate>Mon, 16 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5600096</guid>        </item>
        <item>
            <title>Securing the Supply Chain: Third-Party Contingency Planning for Clinical Trial Transport</title>
            <link>http://www.medworm.com/index.php?rid=5600095&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fdownloads%2Fwhitepapers%2Fmaterials-handling%2Ffilesecuring-the-supply-chain%2F</link>
            <description>Are you certain that your logistics provider can effectively respond to the many unexpected occurrences that threaten to disrupt your carefully conceived budget and timetable? (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5600095</comments>
            <pubDate>Mon, 16 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5600095</guid>        </item>
        <item>
            <title>Pfizer to shun mega-mergers</title>
            <link>http://www.medworm.com/index.php?rid=5586062&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewspfizer-to-shun-mega-mergers</link>
            <description>US Pharmaceutical giant Pfizer will steer clear of mega-mergers for the foreseeable future, the company's chief executive Ian Read told delegates at the JP Morgan Global Healthcare Conference in San Francisco, California, US. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5586062</comments>
            <pubDate>Fri, 13 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5586062</guid>        </item>
        <item>
            <title>Teva eyes Asian expansion</title>
            <link>http://www.medworm.com/index.php?rid=5586061&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsteva-looking-at-asian-expansion</link>
            <description>Israel-based pharmaceutical major Teva is looking towards Asia for acquisitions, hoping to expand into a market where generic use will increase. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5586061</comments>
            <pubDate>Fri, 13 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5586061</guid>        </item>
        <item>
            <title>GSK responds to Argentinian court ruling over controversial vaccine trials</title>
            <link>http://www.medworm.com/index.php?rid=5586064&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsgsk-responds-to-argentinian-court-ruling-over-controversial-vaccine-trials</link>
            <description>GlaxoSmithKline (GSK) will appeal to the Supreme Court of Argentina against a ruling issued by Judge Marcelo Aguinsky over the inadequate handling of administrative conduct during the firm's Clinical Otitis Media and Pneumonia study in 2007-08. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5586064</comments>
            <pubDate>Thu, 12 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5586064</guid>        </item>
        <item>
            <title>Large acquisitions out; research alliances in says Pfizer CEO</title>
            <link>http://www.medworm.com/index.php?rid=5586063&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewslarge-acquisitions-out-research-alliances-in-says-pfizer-ceo</link>
            <description>Pharmaceutical giant Pfizer is unlikely to conduct further acquisitions of large companies, instead focusing its assets on bolt-on purchases and research alliances, according to Pfizer CEO Ian Read. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5586063</comments>
            <pubDate>Thu, 12 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5586063</guid>        </item>
        <item>
            <title>'In-Cell Co-IP' for Visualization of Protein Interactions In Situ</title>
            <link>http://www.medworm.com/index.php?rid=5586068&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fdownloads%2Fwhitepapers%2Fgeneticanalysis%2Ffilevisualization-of-protein-interactions%2F</link>
            <description>Duolink provides a unique capability to study both stable and transient interactions at endogenously expression levels of proteins directly in situ. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5586068</comments>
            <pubDate>Wed, 11 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5586068</guid>        </item>
        <item>
            <title>GlaxoSmithKline fined over controversial vaccine trials on Argentine babies</title>
            <link>http://www.medworm.com/index.php?rid=5586067&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsgsk-fined-over-controversial-vaccine-trials-on-argentinean-babies</link>
            <description>GlaxoSmithKline has been fined by an Argentine court over the management of clinical trials of its pneumonia vaccine Synflorix, which allegedly killed 14 babies. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5586067</comments>
            <pubDate>Wed, 11 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5586067</guid>        </item>
        <item>
            <title>Sensitive Detection of Cytokines in 1μl Serum Samples Using Proseek®</title>
            <link>http://www.medworm.com/index.php?rid=5586066&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fdownloads%2Fwhitepapers%2Fgeneticanalysis%2Ffilesensitive-detection-of-cytokines%2F</link>
            <description>Biomarker research in serological samples and in small laboratory animals is often limited by the large sample volume consumption that traditional technologies require. The Proseek Assay Development kit has been created to lower these hurdles. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5586066</comments>
            <pubDate>Wed, 11 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5586066</guid>        </item>
        <item>
            <title>LX4211 combination therapy found to treat type 2 diabetes</title>
            <link>http://www.medworm.com/index.php?rid=5586065&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewslx4211-combination-therapy-found-to-treat-type-2-diabetes</link>
            <description>Lexicon Pharmaceuticals has announced the top-line results from the first clinical study evaluating the combined effects of LX4211, a sodium glucose transporter 1 and 2 (SGLT1 and SGLT2) inhibitor, with dipeptidyl peptidase 4 (DPP-4) inhibitor sitagl… (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5586065</comments>
            <pubDate>Wed, 11 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5586065</guid>        </item>
        <item>
            <title>Texas prosecutors seek more than $1bn from Johnson &amp; Johnson</title>
            <link>http://www.medworm.com/index.php?rid=5586073&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewstexas-prosecutors-seek-more-than-1bn-from-johnson-johnson</link>
            <description>Prosecutors in Texas are seeking in excess of $1bn in damages from Johnson &amp; Johnson in a lawsuit that alleges the pharmaceutical company overstated the safety of its anti-psychotic drug Risperdal. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5586073</comments>
            <pubDate>Tue, 10 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5586073</guid>        </item>
        <item>
            <title>Autoinjectors: From Planning to Launch</title>
            <link>http://www.medworm.com/index.php?rid=5586072&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fdownloads%2Fwhitepapers%2Fdrug_delivery%2Ffileautoinjectors-planning-to-launch%2F</link>
            <description>Looking at the rising trend towards self-administration therapies, injectable drug delivery devices such as pen injectors, autoinjectors and needle-free injectors show a significant growth potential in the near future. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5586072</comments>
            <pubDate>Tue, 10 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5586072</guid>        </item>
        <item>
            <title>Introducing Proseek - The 1µl 'ELISA'</title>
            <link>http://www.medworm.com/index.php?rid=5586071&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fgeneticanalysis%2Folink-bioscience%2Fpressolink-proseek.html</link>
            <description>Proseek is a user friendly, open format reagent kit system for the detection and quantification of proteins in solution. It offers the same level of simplicity and openness as ELISA but with some major advantages. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5586071</comments>
            <pubDate>Tue, 10 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5586071</guid>        </item>
        <item>
            <title>Aeras and China biotec group to develop new TB vaccines</title>
            <link>http://www.medworm.com/index.php?rid=5586070&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsaeras-and-china-biotec-group-to-develop-new-tb-vaccines</link>
            <description>US vaccine manufacturer Aeras and the China National Biotec Group (CNBG) have reached an agreement to jointly develop new tuberculosis (TB) vaccines. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5586070</comments>
            <pubDate>Tue, 10 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5586070</guid>        </item>
        <item>
            <title>Introducing SHL's First White Paper - 'Autoinjectors: From Planning to Launch'</title>
            <link>http://www.medworm.com/index.php?rid=5586069&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fdrug_delivery%2Fshl-group%2Fpressshl-autoinjector-whitepaper.html</link>
            <description>SHL is officially introducing the company's first white paper on the topic of 'Autoinjectors: From Planning to Launch' with the goal of sharing with readers insights on how to prepare for the overall development process from different perspectives, i… (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5586069</comments>
            <pubDate>Tue, 10 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5586069</guid>        </item>
        <item>
            <title>Bristol-Myers Squibb unveils $2.5bn plans to acquire Inhibitex</title>
            <link>http://www.medworm.com/index.php?rid=5586074&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsbristol-myers-squibb-unveils-25bn-plans-to-acquire-inhibitex</link>
            <description>Bristol-Myers Squibb has unveiled plans to acquire the hepatitis C specialist Inhibitex in a deal valued at approximately $2.5bn. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5586074</comments>
            <pubDate>Mon, 09 Jan 2012 11:32:13 +0100</pubDate>
            <guid isPermaLink="false">5586074</guid>        </item>
        <item>
            <title>SHL Receives a Great Response at the 2011 PDA in Basel</title>
            <link>http://www.medworm.com/index.php?rid=5586077&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fdrug_delivery%2Fshl-group%2Fpressshl-pda-basel.html</link>
            <description>SHL successfully wrapped up this year's exhibition at the PDA's 'The Universe of Pre-filled Syringes and Injection Devices' 2011 event held in Basel, Switzerland, earlier last month. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5586077</comments>
            <pubDate>Mon, 09 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5586077</guid>        </item>
        <item>
            <title>SHL Featured in an Article on the Topic of 'The Emerging Drug Delivery Landscape'</title>
            <link>http://www.medworm.com/index.php?rid=5586076&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fdrug_delivery%2Fshl-group%2Fpressshl-emerging-drug-delivery.html</link>
            <description>SHL was recently featured in an article published by BioSpectrum Asia on the topic of 'The Emerging Drug Delivery Landscape'. In the article, SHL is identified as an innovator of auto injectors in Asia and continues to respond to increasing demands b… (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5586076</comments>
            <pubDate>Mon, 09 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5586076</guid>        </item>
        <item>
            <title>Inhaled Parkinson’s drug shows positive results</title>
            <link>http://www.medworm.com/index.php?rid=5586075&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsinhaled-parkinsons-drug-shows-positive-results</link>
            <description>An inhaled drug for the treatment of Parkinson's disease has shown positive results in a Phase I clinical trial, US-based Civitas Therapeutics has announced. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5586075</comments>
            <pubDate>Mon, 09 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5586075</guid>        </item>
        <item>
            <title>Research collaboration in the cloud: how NCI and research partners are using interoperable digital identities, digital signatures and cloud computing to accelerate drug development</title>
            <link>http://www.medworm.com/index.php?rid=5573501&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fdownloads%2Fwhitepapers%2Fwastewater%2Ffileresearch-collaboration-in-the-cloud-how-nci-and-research-partners-are-using-interoperable-digital-identities-digital-signatures-and-cloud-computing-to-accelerate-drug-development%2F</link>
            <description>This paper summarises the pilot study involving government and industry cancer researchers, indicating that the use of interoperable digital identities, digital signatures and cloud computing will accelerate the initiation of a clinical trials, while… (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5573501</comments>
            <pubDate>Fri, 06 Jan 2012 11:22:00 +0100</pubDate>
            <guid isPermaLink="false">5573501</guid>        </item>
        <item>
            <title>Kilitch Drugs Manufacturing Plant</title>
            <link>http://www.medworm.com/index.php?rid=5586078&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fprojects%2Fkilitch-drugs-manufacturing-plant%2F</link>
            <description>Indian pharmaceuticals manufacturing company Kilitch Drugs produces and markets drug formulations in solid, liquid and parenteral dosage forms. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5586078</comments>
            <pubDate>Fri, 06 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5586078</guid>        </item>
        <item>
            <title>Hospira facing pressure over execution drug</title>
            <link>http://www.medworm.com/index.php?rid=5573504&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewshospira-facing-pressure-over-execution-drug</link>
            <description>US-based pharmaceutical firm Hospira is facing pressure from an international group of 25 doctors over the use of muscle-relaxant drug pancuronium in executions within the US. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5573504</comments>
            <pubDate>Fri, 06 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5573504</guid>        </item>
        <item>
            <title>AstraZeneca to pursue development of Targacept’s Alzheimer’s candidate</title>
            <link>http://www.medworm.com/index.php?rid=5573503&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsastrazeneca-to-pursue-development-of-targacepts-alzheimers-candidate</link>
            <description>Targacept has announced that AstraZeneca will pursue the development of the company's candidate AZD1446 as a treatment for Alzheimer's disease. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5573503</comments>
            <pubDate>Fri, 06 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5573503</guid>        </item>
        <item>
            <title>3M Reveals Advanced Bio Filters Setting New Flow-Rate, Organism-Reduction and Efficiency Benchmarks</title>
            <link>http://www.medworm.com/index.php?rid=5573502&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fpurification%2F3m-purification%2Fpress3m-advanced-bio-filters.html</link>
            <description>Diversified technology company 3M has launched a range of bioburden reduction filters combining the high filtration performance of membrane-type media with enhanced flow characteristics, enabling lower system costs and longer operating lifetimes. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5573502</comments>
            <pubDate>Fri, 06 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5573502</guid>        </item>
        <item>
            <title>3M Purification-Filtration and Purification Technologies for the Pharmaceutical Industry</title>
            <link>http://www.medworm.com/index.php?rid=5562862&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fpurification%2F3m-purification%2F</link>
            <description>3M Purification's team of specialists provides technical and regulatory support to the pharmaceutical and biopharmaceutical industries and to the water filtration market. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5562862</comments>
            <pubDate>Wed, 04 Jan 2012 01:00:00 +0100</pubDate>
            <guid isPermaLink="false">5562862</guid>        </item>
        <item>
            <title>BioInvent and Servier to explore oncology target</title>
            <link>http://www.medworm.com/index.php?rid=5562864&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsbioinvent-and-servier-to-explore-oncology-target</link>
            <description>BioInvent International and Les Laboratoires Servier (Servier) have entered into an antibody collaboration to explore the value of an oncology target involved in tumour cell metabolism. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5562864</comments>
            <pubDate>Wed, 04 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5562864</guid>        </item>
        <item>
            <title>Bristol-Myers Squibb named Best Big Drug Company of 2011</title>
            <link>http://www.medworm.com/index.php?rid=5562863&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsbristol-myers-squibb-named-best-big-drug-company-of-2011</link>
            <description>Bristol-Myers Squibb has been named 'Best Big Drug Company of 2011' by US-based business magazine Forbes on the back of a 32% share price hike over the course of the year. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5562863</comments>
            <pubDate>Wed, 04 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5562863</guid>        </item>
        <item>
            <title>Mozambique to produce its own antiretrovirals</title>
            <link>http://www.medworm.com/index.php?rid=5562866&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsmozambique-to-produce-its-own-antiretrovirals</link>
            <description>Mozambique health minister Alexandre Manguele has confirmed that the country will begin producing its own antiretrovirals to combat high HIV rates, becoming the first African country to do so outside of the private sector. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5562866</comments>
            <pubDate>Tue, 03 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5562866</guid>        </item>
        <item>
            <title>Bayer and Johnson &amp; Johnson seek new approval for Xarelto</title>
            <link>http://www.medworm.com/index.php?rid=5562865&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsbayer-and-johnson-johnson-seek-new-approval-for-xarelto</link>
            <description>Bayer and Johnson &amp; Johnson are seeking a new approval for the anticoagulant Xarelto, representing a third use for the drug. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5562865</comments>
            <pubDate>Tue, 03 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5562865</guid>        </item>
        <item>
            <title>Balda Medical Extends Clean Room Capacity at its Site in Germany</title>
            <link>http://www.medworm.com/index.php?rid=5562867&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fdrug_delivery%2Fbalda-medical%2Fpressbalda-extends-clean-room-capacity.html</link>
            <description>Due to new project orders for production of diagnostic and pharmaceutical consumables Balda Medical has recently enlarged its clean room capacity by 50% to 2,500 square metres. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5562867</comments>
            <pubDate>Mon, 02 Jan 2012 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5562867</guid>        </item>
        <item>
            <title>Roche New Research and Development Facility</title>
            <link>http://www.medworm.com/index.php?rid=5539844&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fprojects%2Froche-new-research-and-development-facility%2F</link>
            <description>Roche's new R&amp;D facility is located in Wettsteinallee near Basel, Switzerland. It was officially inaugurated in November 2011. Roche made an investment of $271m in the site. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5539844</comments>
            <pubDate>Fri, 23 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5539844</guid>        </item>
        <item>
            <title>Actavis to launch new pain drug in the US</title>
            <link>http://www.medworm.com/index.php?rid=5539843&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsactavis-to-launch-new-pain-drug-in-the-us</link>
            <description>Actavis Inc has entered into a partnership with QRxPharma to commercialise MoxDuo IR in the US. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5539843</comments>
            <pubDate>Fri, 23 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5539843</guid>        </item>
        <item>
            <title>Season's Greetings from the editorial team</title>
            <link>http://www.medworm.com/index.php?rid=5539842&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsseasons-greetings</link>
            <description>We will be taking a short break over the holiday season. Our daily news service will return in full on 3 January. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5539842</comments>
            <pubDate>Fri, 23 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5539842</guid>        </item>
        <item>
            <title>Takeda boosts oncology pipeline with Intellikine acquisition</title>
            <link>http://www.medworm.com/index.php?rid=5527849&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewstakeda-boosts-oncology-pipeline-with-intellikine-acquisition</link>
            <description>Takeda has acquired molecule specialist Intellikine through its Takeda America Holdings subsidiary, a move that will add two oncology candidates to its drug pipeline. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5527849</comments>
            <pubDate>Thu, 22 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5527849</guid>        </item>
        <item>
            <title>GlaxoSmithKline shears off over-the-counter brands</title>
            <link>http://www.medworm.com/index.php?rid=5527848&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsglaxosmithkline-shears-off-over-the-counter-brands</link>
            <description>GlaxoSmithKline is to will divest a number of non-core over-the-counter brands in the US, Canada and Europe to Prestige Brands Holdings for £426m. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5527848</comments>
            <pubDate>Thu, 22 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5527848</guid>        </item>
        <item>
            <title>FDA to review Pfizer’s experimental arthritis drug</title>
            <link>http://www.medworm.com/index.php?rid=5527852&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsfda-to-review-pfizers-experimental-arthritis-drug</link>
            <description>The US Food and Drug Administration (FDA) has accepted a new drug application for tofacitinib, an experimental drug to treat moderately to severely active rheumatoid arthritis, for review. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5527852</comments>
            <pubDate>Wed, 21 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5527852</guid>        </item>
        <item>
            <title>FDA awards Catalyst cocaine dependency drug fast-track status</title>
            <link>http://www.medworm.com/index.php?rid=5527851&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsfda-awards-catalyst-cocaine-dependency-drug-fast-track-status</link>
            <description>Catalyst Pharmaceutical Partners has received fast-track designation from the US food and Drug Administration (FDA) for CPP-115, a novel drug to treat cocaine dependency. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5527851</comments>
            <pubDate>Wed, 21 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5527851</guid>        </item>
        <item>
            <title>Wallace Wurth Biomedical Research Centre</title>
            <link>http://www.medworm.com/index.php?rid=5527850&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fprojects%2Fwallace-wurth-biomedical-research-centre%2F</link>
            <description>The Wallace Wurth Building is the most recognisable building at the Kensington Campus in the premises of the University of New South Wales (UNSW) in Sydney, Australia. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5527850</comments>
            <pubDate>Wed, 21 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5527850</guid>        </item>
        <item>
            <title>Amgen and Watson link up to develop cancer drugs</title>
            <link>http://www.medworm.com/index.php?rid=5527856&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsamgen-and-watson-link-up-to-develop-cancer-drugs</link>
            <description>US-based Amgen and Watson Pharmaceuticals will collaborate to develop several oncology antibody biosimilar medicines. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5527856</comments>
            <pubDate>Tue, 20 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5527856</guid>        </item>
        <item>
            <title>Kemwell-Contract Manufacturing and Development, Packaging and Global Distribution</title>
            <link>http://www.medworm.com/index.php?rid=5527855&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fcontract%2Fkemwell-contract%2F</link>
            <description>Kemwell is a leading pharmaceutical contract development and manufacturing company. With headquarters in Bangalore, India, we employ more than 1,000 people across our manufacturing facilities in Indi... (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5527855</comments>
            <pubDate>Tue, 20 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5527855</guid>        </item>
        <item>
            <title>AstraZeneca hit by further drug development disappointment</title>
            <link>http://www.medworm.com/index.php?rid=5527854&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsastrazeneca-hit-by-further-drug-development-disappointment</link>
            <description>UK-based pharmaceutical firm AstraZeneca has been hit by further disappointments in its drug development efforts, announcing a $381.5m charge in the fourth quarter following poor results from two new drugs. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5527854</comments>
            <pubDate>Tue, 20 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5527854</guid>        </item>
        <item>
            <title>Farmak-Active Pharmaceutical Ingredients and Intermediates</title>
            <link>http://www.medworm.com/index.php?rid=5527853&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fmaterials%2Ffarmak%2F</link>
            <description>Farmak is a traditional Czech-based company specialized in the field of API and fine chemicals manufacturing. Chemical production has been running at its manufacturing site since 1934, and for the pa... (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5527853</comments>
            <pubDate>Tue, 20 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5527853</guid>        </item>
        <item>
            <title>Future oncology: The path to personalised medicine</title>
            <link>http://www.medworm.com/index.php?rid=5527857&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Ffeatures%2Ffeaturefuture-oncology-the-path-to-personalised-medicine%2F</link>
            <description>Could the genetic screening of tumour tissues push oncology into the era of personalised patient cancer treatment? Elisabeth Fischer talks to the researchers of the Stratified Cancer Programme in the UK and finds out how looking at cancer mutations c… (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5527857</comments>
            <pubDate>Mon, 19 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5527857</guid>        </item>
        <item>
            <title>Global Vision-Automated Proofreading and Inspection Solutions for the Entire Pharmaceutical Workflow</title>
            <link>http://www.medworm.com/index.php?rid=5516849&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fconsult%2Fglobal-vision%2F</link>
            <description>With more than a decade of experience working closely with international pharmaceutical clients, Global Vision continuously strives to increase proofreading accuracy, employee productivity and process efficiencies throughout the pharmaceutical workfl… (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5516849</comments>
            <pubDate>Mon, 19 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5516849</guid>        </item>
        <item>
            <title>Two pharma employees killed in India reactor blast</title>
            <link>http://www.medworm.com/index.php?rid=5516848&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewstwo-pharma-employees-killed-in-india-reactor-blast</link>
            <description>Two employees at Rantus Pharma have been killed in a huge fire at the company's chemical plant in the Medak district of India, about 50km from Hyderabad. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5516848</comments>
            <pubDate>Mon, 19 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5516848</guid>        </item>
        <item>
            <title>HPA Case Study: Production of Non-GMP Biologicals</title>
            <link>http://www.medworm.com/index.php?rid=5516847&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fdownloads%2Fwhitepapers%2Fcontract%2Ffilenon-gmp-biologicals%2F</link>
            <description>The Process &amp; Analytical Development Group has supplied a variety of customers with a broad range of microbial products. Our expertise in protein analysis and enzymology mean that our products are well-characterised and of the required quality. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5516847</comments>
            <pubDate>Mon, 19 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5516847</guid>        </item>
        <item>
            <title>Health Protection Agency-Healthcare Product Research, Development and GMP Manufacture</title>
            <link>http://www.medworm.com/index.php?rid=5516846&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fcontract%2Fhpa%2F</link>
            <description>The Health Protection Agency has been working with the pharmaceutical industry for over 50 years, undertaking contract research, development and manufacture of healthcare products. This includes expe... (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5516846</comments>
            <pubDate>Mon, 19 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5516846</guid>        </item>
        <item>
            <title>Priorclave's C60 Model Autoclave Draws Visitors at London Vet Show</title>
            <link>http://www.medworm.com/index.php?rid=5516845&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Flab_equip%2Fpriorclave-autoclaves%2Fpressautoclave-vet-show.html</link>
            <description>During the recent London Vet Show the autoclave featured on the Southwest Medical stand proved popular with visitors. Supplied by Priorclave, one of the UK's top autoclave manufacturers, the C60 model surprised visitors with its compact outward physi… (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5516845</comments>
            <pubDate>Mon, 19 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5516845</guid>        </item>
        <item>
            <title>HPA Case Study: Development of a Manufacturing Process for a Biodefence Vaccine</title>
            <link>http://www.medworm.com/index.php?rid=5516844&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fdownloads%2Fwhitepapers%2Fcontract%2Ffilebiodefence-vaccine-manufacturing%2F</link>
            <description>The Process &amp; Analytical Development Group (PADG) has recently completed the final development of a manufacturing process for an important biodefence vaccine on behalf of a US contractor. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5516844</comments>
            <pubDate>Mon, 19 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5516844</guid>        </item>
        <item>
            <title>AstraZeneca’s Faslodex given final snub by NICE</title>
            <link>http://www.medworm.com/index.php?rid=5516843&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsastrazenecas-faslodex-given-final-snub-by-nice</link>
            <description>The UK's National Institute for Health and Clinical Excellence (NICE) has snubbed AstraZeneca breast cancer drug Faslodex in its final guidance, deeming it an inefficient use of NHS resources. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5516843</comments>
            <pubDate>Mon, 19 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5516843</guid>        </item>
        <item>
            <title>HPA Case Study: Technical Support for FDA Licensure of Erwinaze™</title>
            <link>http://www.medworm.com/index.php?rid=5516842&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fdownloads%2Fwhitepapers%2Fcontract%2Ffilefda-licensure-erwinaze%2F</link>
            <description>Erwinaze™, a biotherapeutic used for the treatment of acute lymphoblastic leukemia (ALL), is manufactured by the HPA in its cGMP facilities at Porton Down and is currently distributed to over 50 countries worldwide by EUSA Pharma. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5516842</comments>
            <pubDate>Mon, 19 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5516842</guid>        </item>
        <item>
            <title>HPA Case Study: Analytical Method Development</title>
            <link>http://www.medworm.com/index.php?rid=5516841&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fdownloads%2Fwhitepapers%2Fcontract%2Ffileanalytical-method-development%2F</link>
            <description>Regulatory authorities are increasingly placing greater emphasis on analytical methods in manufacturing. This is particularly so with biopharmaceuticals where the requirement is often for a wide, diverse range of analytical methods to fully understan… (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5516841</comments>
            <pubDate>Mon, 19 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5516841</guid>        </item>
        <item>
            <title>York University Department of Biology to Take Delivery of Priorclave Autoclaves</title>
            <link>http://www.medworm.com/index.php?rid=5516840&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Flab_equip%2Fpriorclave-autoclaves%2Fpressyork-university-biology-autoclaves.html</link>
            <description>The addition of Priorclave autoclaves at York University ensures that the biology department, which is recognised as one of the leading biological science departments in the UK, maintains the highest of standards in sterilisation in the laboratory to… (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5516840</comments>
            <pubDate>Mon, 19 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5516840</guid>        </item>
        <item>
            <title>Prefilled syringes: Getting to the point</title>
            <link>http://www.medworm.com/index.php?rid=5507482&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Ffeatures%2Ffeatureprefilled-syringes-getting-to-the-point%2F</link>
            <description>The many benefits of prefilled syringes are fuelling one of the medical device industry's fastest-growing markets. Chris Lo rolls up his sleeves to explore the finely-honed science behind ready-to-use syringes. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5507482</comments>
            <pubDate>Fri, 16 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5507482</guid>        </item>
        <item>
            <title>US cracks down on prescription drug delays</title>
            <link>http://www.medworm.com/index.php?rid=5507481&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsus-cracks-down-on-prescription-drug-delays</link>
            <description>The Obama Administration has issued an interim final rule to help prevent prescription drug shortages in the US. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5507481</comments>
            <pubDate>Fri, 16 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5507481</guid>        </item>
        <item>
            <title>GSK announces Huntington’s pact with University of Dundee</title>
            <link>http://www.medworm.com/index.php?rid=5507480&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsgsk-announces-huntingtons-pact-with-university-of-dundee</link>
            <description>UK-based pharmaceutical major GlaxoSmithKline has signed a pact with the University of Dundee, UK, to investigate a potential treatment for Huntington’s disease. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5507480</comments>
            <pubDate>Fri, 16 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5507480</guid>        </item>
        <item>
            <title>UK cancer treatment costs to spiral by 2021</title>
            <link>http://www.medworm.com/index.php?rid=5507486&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsuk-cancer-treatment-costs-to-spiral-by-2021</link>
            <description>The costs associated with the diagnosis and treatment of cancer in the UK will dramatically increase by 2021, according to a new report published by private healthcare provider Bupa. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5507486</comments>
            <pubDate>Thu, 15 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5507486</guid>        </item>
        <item>
            <title>Pierre Fabre Médicament - SuperCritical Fluids Division to Exhibit at DDP 2012</title>
            <link>http://www.medworm.com/index.php?rid=5507485&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fdrug_delivery%2Fplantes%2Fpresspierre-fabre-ddp.html</link>
            <description>Pierre Fabre Médicament - SuperCritical Fluids Division will be an exhibitor at DDP 2012 in Las Vegas (25-27 January). (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5507485</comments>
            <pubDate>Thu, 15 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5507485</guid>        </item>
        <item>
            <title>AstraZeneca compounds now available to UK researchers</title>
            <link>http://www.medworm.com/index.php?rid=5507484&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsastrazeneca-compounds-now-available-to-uk-researchers</link>
            <description>A landmark agreement between the UK Medical Research Council (MRC) and AstraZeneca will allow researchers free access to a number of high potential compounds. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5507484</comments>
            <pubDate>Thu, 15 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5507484</guid>        </item>
        <item>
            <title>Sanford Consortium for Regenerative Medicine's Stem Cell Research Facility</title>
            <link>http://www.medworm.com/index.php?rid=5507483&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fprojects%2Fsanford-consortium-for-regenerative-medicines-stem-cell-research-facility%2F</link>
            <description>The Sanford Consortium for Regenerative Medicine (SCRM) inaugurated a new stem cell research facility in La Jolla in the state of California, US, in November 2011. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5507483</comments>
            <pubDate>Thu, 15 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5507483</guid>        </item>
        <item>
            <title>Pharma Technology Focus - Issue 8</title>
            <link>http://www.medworm.com/index.php?rid=5507490&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Ffeatures%2Ffeaturepharma-technology-focus-issue-8%2F</link>
            <description>In this issue we look at securing supply chains and optimising logistics. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5507490</comments>
            <pubDate>Wed, 14 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5507490</guid>        </item>
        <item>
            <title>Safety of MS drug questioned after patient dies</title>
            <link>http://www.medworm.com/index.php?rid=5507489&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsms-drug-safety-questioned-after-patient-dies</link>
            <description>The safety of Novartis’ multiple sclerosis drug Gilenya is under investigation after a patient in the US died after taking the treatment for the first time. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5507489</comments>
            <pubDate>Wed, 14 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5507489</guid>        </item>
        <item>
            <title>GSK subsidiary charged with fraud</title>
            <link>http://www.medworm.com/index.php?rid=5507488&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsgsk-subsidiary-charged-with-fraud</link>
            <description>Stiefel Laboratories, a subsidiary of GlaxoSmithKline, has been charged with fraud by the US Securities and Exchange Commission (SEC) after stock was repurchased at severely undervalued prices. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5507488</comments>
            <pubDate>Wed, 14 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5507488</guid>        </item>
        <item>
            <title>Boehringer Ingelheim's US Headquarters</title>
            <link>http://www.medworm.com/index.php?rid=5507487&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fprojects%2Fboehringer-ingelheims-us-headquarters%2F</link>
            <description>Germany-based privately held pharmaceutical company Boehringer Ingelheim is involved in drug discovery, development and manufacturing. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5507487</comments>
            <pubDate>Wed, 14 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5507487</guid>        </item>
        <item>
            <title>Aveva-Transdermal Drug Delivery Systems</title>
            <link>http://www.medworm.com/index.php?rid=5496962&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fdrug_delivery%2Favera%2F</link>
            <description>The ideal partner to bring your product to commercial success, offering a breadth of transdermal innovation from a depth of experience.Aveva Drug Delivery Systems is a Nitto Denko company, which is o... (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5496962</comments>
            <pubDate>Tue, 13 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5496962</guid>        </item>
        <item>
            <title>ILC Dover-Flexible Powder Containment Technologies</title>
            <link>http://www.medworm.com/index.php?rid=5496961&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fpackaging%2Filcdover%2F</link>
            <description>ILC Dover offers flexible powder containment technologies, eliminating many of the problems associated with the use of traditional metal and glass systems for the pharmaceutical industry. The company... (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5496961</comments>
            <pubDate>Tue, 13 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5496961</guid>        </item>
        <item>
            <title>Glenmark to seek Napo arbitration</title>
            <link>http://www.medworm.com/index.php?rid=5496960&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsglenmark-to-seek-napo-arbitration</link>
            <description>Glenmark Pharmaceuticals has said that it will seek an arbitration in the US following the termination of an agreement with Napo Pharmaceuticals, with Glenmark claiming there was no basis for the termination. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5496960</comments>
            <pubDate>Tue, 13 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5496960</guid>        </item>
        <item>
            <title>Vaximm to launch first oral cancer vaccine study</title>
            <link>http://www.medworm.com/index.php?rid=5496959&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsvaximm-to-launch-first-oral-cancer-vaccine-study</link>
            <description>Vaximm AG will start a clinical trial on the first ever investigational oral cancer vaccine, the company announced today. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5496959</comments>
            <pubDate>Tue, 13 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5496959</guid>        </item>
        <item>
            <title>Breast cancer patients quit drugs due to severe side-effects, study finds</title>
            <link>http://www.medworm.com/index.php?rid=5496966&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsbreast-cancer-patients-quit-drugs-due-to-severe-side-effects-study-finds</link>
            <description>A US study has revealed that 36% of postmenopausal breast cancer patients stop taking medication early because side effects are more severe than they expect. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5496966</comments>
            <pubDate>Mon, 12 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5496966</guid>        </item>
        <item>
            <title>Dividella-Toploading, Wallet and BoxWallet® Packaging Machines</title>
            <link>http://www.medworm.com/index.php?rid=5496965&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fmachines-labelling%2Fdividella2%2F</link>
            <description>Within the Körber Medipak Group, as specialists in the development and manufacture of machinery for the pharmaceutical industry we have established ourselves as the centre of competency for parentera... (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5496965</comments>
            <pubDate>Mon, 12 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5496965</guid>        </item>
        <item>
            <title>Furiex shares fall as it halts cholesterol drug development</title>
            <link>http://www.medworm.com/index.php?rid=5496964&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsfuriex-shares-fall-as-it-halts-cholesterol-drug-development</link>
            <description>US-based Furiex Pharmaceuticals' shares have fallen more than 11% after it announced that it would stop developing PPD-10558, an investigational drug to treat high cholesterol. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5496964</comments>
            <pubDate>Mon, 12 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5496964</guid>        </item>
        <item>
            <title>Owen Mumford-Automatic Injection Pens and Auto Injectors for Self-Injection</title>
            <link>http://www.medworm.com/index.php?rid=5496963&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fcontractors%2Fdrug_delivery%2Fowen%2F</link>
            <description>With a proven track record and more than 50 years' experience in the medical device arena, Owen Mumford has become a specialist in the design, development and manufacture of customised, automatic inj... (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5496963</comments>
            <pubDate>Mon, 12 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5496963</guid>        </item>
        <item>
            <title>Major drug firms come together to launch huge pharma database</title>
            <link>http://www.medworm.com/index.php?rid=5489130&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsmajor-drug-firms-come-together-to-launch-huge-pharma-database</link>
            <description>IBM and three major drug companies have donated a huge web of pharmaceutical and chemical data to the US National Institutes of Health to help researchers gain an insight into future drug molecules. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5489130</comments>
            <pubDate>Fri, 09 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5489130</guid>        </item>
        <item>
            <title>Snapshot: Can increased collaboration between big pharma and academia counter industry issues?</title>
            <link>http://www.medworm.com/index.php?rid=5489129&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Ffeatures%2Ffeaturesnapshot-can-increased-collaboration-between-big-pharma-and-academia-counter-rd-patent-and-approval-issues-in-the-industry%2F</link>
            <description>Faced with record low approval rates and a looming patent wall, collaborations are becoming growingly important. Using detailed market data, this snapshot charts the shifting nature of an industry which has begun to realise that a change in strategy … (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5489129</comments>
            <pubDate>Fri, 09 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5489129</guid>        </item>
        <item>
            <title>AstraZeneca slashes US sales team</title>
            <link>http://www.medworm.com/index.php?rid=5489128&amp;cid=s_22572_34_f&amp;fid=22572&amp;url=http%3A%2F%2Fwww.pharmaceutical-technology.com%2Fnews%2Fnewsastrazeneca-slashes-us-sales-team</link>
            <description>AstraZeneca will cut its US-based sales team by 1,150 as part of efforts to streamline its operations in the country. (Source: Pharmaceutical Technology)</description>
            <author>Pharmaceutical Technology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5489128</comments>
            <pubDate>Fri, 09 Dec 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">5489128</guid>        </item>
    </channel>
</rss>

